Personalized p-THYROSIM model for thyroid hormone dynamics, hypothyroidism treatment & implementation in an iOS version for wide distribution

p-THYROSIM can predictively provide accurate mono- and combination LT4+LT3 replacement hormone therapies for male and female hypothyroid patients, personalized with their <i>H</i>s and <i>W</i>s. Where combination therapy is warranted, our results predict that not much LT3 (typically 5 - 7.5 ug) is needed in addition to LT4 to restore euthyroid levels, with larger LT3 doses rarely needed, suggesting opportunities for further research exploring safe and effective combination therapy with lower T3 doses and slow-releasing T3 formulations.